Dr. Klaus Breiner is a Partner at Bellevue Group in Kusnacht/Zurich, Switzerland. Bellevue Group is an independent financial firm listed on the Swiss Exchange (BBN.SW) specializing in investment banking and asset management. With over $3 billion under management, the Group is one of the largest financial healthcare investors in the world, investing in both private and public equity. Before joining Bellevue in 2004 to launch and manage BB BIOTECH VENTURES II, Dr. Breiner was Investment Manager at Global Life Science Ventures (GLSV) in Munich. Prior to that, he was a business consultant with Booz Allen & Hamilton in Zurich and a researcher at the Swiss Institute of Technology (ETH). In addition to ORTHOCON, Dr. Breiner currently is a director at Alpex Pharma SA and Pevion Biotech AG. Dr. Breiner holds a MA in chemistry from the University of North Carolina, Chapel Hill, and a PhD in Molecular Biology from ZMBH/University of Heidelberg. |